All patients were referred for treatment of lesions that had not shown spontaneous regression with continued growth following first-line or other therapies and, thus, were concerning for a diagnosis of CD30+ LPD. This evidence concerns the gene TNFRSF8 and disseminated peritoneal leiomyomatosis.